A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Trial Profile

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Valbenazine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Therapeutic Use
  • Acronyms KINECT; KINECT-1
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 07 Dec 2017 Results (n=400) assessing the cardiovascular effects of once-daily valbenazine using pooled data from three 6-week, double-blind, placebo-controlled trials (KINECT, KINECT 2, and KINECT 3) and the 42-week valbenazine extension period of KINECT 3, published in the Drug Safety Journal.
    • 04 Dec 2017 According to a Neurocrine Biosciences media release, Results (n=373) of pooled population from KINETIC-1,KINETIC-2,KINETIC-3 studies presented at the College of Neuropsychopharmacology (ACNP) Annual Meeting.
    • 08 Jun 2017 Results (n=373) of pooled population from KINETIC-1,KINETIC-2,KINETIC-3 studies presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top